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Background: The dominant diagnostic model of the classification of depression today is unitarian; however, since
Kurt Schneider (1920) introduced the concept of endogenous depression and reactive depression, the binary model
has still often been used on a clinical basis. Notwithstanding this, to our knowledge, there have been no collective
data on how psychiatrists differentiate these two conditions. We therefore conducted a survey to examine how
psychiatrists in Japan differentiate patients with major depressive disorder who present mainly with melancholic
features and those with reactive features.
Methods: Three case scenarios of melancholic and reactive depression, and one-in-between were prepared. These
cases were designed to present with at least 5 symptoms listed in the DSM-IV-TR with severity being mild. We have
sent the questionnaires regarding treatment options and diagnosis for those three cases on a 7-point Likert scale
(1 = “not appropriate”, 4 = “cannot tell”, and 7 = “appropriate”). Five hundred and two psychiatrists from over one
hundred hospitals and community clinics throughout Japan have participated in this survey.
Results: The melancholic case resulted significantly higher than the reactive case on either antidepressants
(mean ± SD: 5.9 ± 1.2 vs. 3.6 ± 1.7, p < 0.001), hypnotics (mean ± SD: 5.5 ± 1.1 vs. 5.0 ± 1.3, p < 0.001), and
electroconvulsive therapy (mean ± SD: 1.5 ± 0.9 vs. 1.2 ± 0.6, p < 0.001). On the other hand, the reactive case resulted
in significantly higher scores compared to the melancholic case and the one- in-between cases in regards to
psychotherapy (mean ± SD: 4.9 ± 1.4 vs. 4.3 ± 1.4 vs. 4.7 ± 1.5, p < 0.001, respectively). Scores for informing patients
that they suffered from “depression” were significantly higher in the melancholic case, compared to the reactive
case (mean ± SD: 4.7 ± 1.7 vs. 2.2 ± 1.4, p < 0.001).
Conclusions: Japanese psychiatrists distinguish between major depressive disorder with melancholic and reactive
features, and thus choose different treatment strategies regarding pharmacological treatment and psychotherapy.
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While the classification of depression has long been a
contentious issue, the dominant diagnostic model today
is unitarian (i.e. there is only one type of depression,
which varies by severity) [1]. Both of the widely accepted
diagnostic systems, the Diagnostic and Statistical Manual* Correspondence: jtmizushima@gmail.com
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reproduction in any medium, provided the orof Mental Disorders, Fourth Edition (DSM-IV) and the
International Statistical Classification of Diseases and
Related Health Problems, 10th Revision (ICD-10), are
based on using symptom check list criteria for diagnosis
and assessment of severity [2-4]. Similarly, several well-
known clinical guidelines for major depressive disorder
(MDD) recommend treatments solely depending on the
severity of depression, but they do not refer to the pres-
ence of psychogenic depression [5,6].
Heterogeneity of patients with depression based on
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effective clinical care, evaluation of new interventions,
and research on pathophysiology [2]. Even recently,
Ghaemi and Vohringer pointed out that most depressive
conditions can be shown to be about equally genetic and
environmental. They also state that neurotic depression
that is synonymous to reactive depression has a com-
pletely different psychopathological picture from melan-
cholia [7]. Melancholia is characterized by a number of
features such as disturbances in affect, psychomotor
disturbances, cognitive impairment, vegetative dysfunc-
tions, and psychosis. It has also been named in a variety
of ways, including “endogenous” depression [8]; in fact,
in Japan, “melancholia” is considered synonymous with
“endogenous”. Furthermore, they may also differ markedly
in treatment response; melancholia is more likely respon-
sive to at least some antidepressants compared to neurotic
depression [7]. Moreover, the presence of melancholia has
been reported to predict a poor response to psychotherapy
and placebo and a relatively good response to antidepres-
sants and electroconvulsive therapy [9].
Since Kurt Schneider introduced the concept of mel-
ancholic depression and reactive depression [10], the
binary model classifying depression into two principal
types has often been used on a clinical basis. In the
1960s, members of the so-called Newcastle school sup-
ported the binary view with their multivariate analyses
and formed criteria, which divided depression into mel-
ancholic depression and reactive depression [11-13].
Even recently, these components are still expected to be
critically important and useful in actual clinical settings
as mentioned above. However, to our knowledge, there
have been no collective data on how psychiatrists differ-
entiate the diagnosis and treatment between melancholic
depression and reactive depression. This information
would be expected to improve our understanding of ac-
tual clinical practice for these psychiatric conditions and
help us enhance our treatment strategies. Therefore, we
set up an investigation to find out how psychiatrists in
Japan differentiate clinical care between patients with
MDD who present mainly with melancholic features and
those with reactive features.
Methods
This survey was conducted from November 1, 2010 until
January 30, 2011. Psychiatrists working in psychiatric
hospitals, general hospitals, university hospitals, and
community clinics in Japan were asked to participate
in this survey. Three imaginary case scenarios of melan-
cholic depression, reactive depression, and one-in-between
were prepared, and reviewed by expert psychiatrists (see
Additional file 1) for the questionnaire. All three cases fulfill
the diagnosis of MDD according to the DSM-IV-TR [3];
when making the cases, these cases were designed topresent with at least 5 symptoms listed in the DSM-IV-TR
with severity being mild. On the other hand, what made
these three case scenarios different were the scores
of the Newcastle Scale 2nd edition (NCS-II) (see
Additional file 2) [12,13]. The NCS-II comprises two
positively and seven negatively weighted items which
are summed to give a diagnostic score, -19 and above
indicating reactive depression, and −20 and below
endogenous depression [12,13]. Melancholic, reactive,
and one-in-between cases were prepared with target
NCS-II scores of −40, 15 and −20, respectively. Subse-
quently, 11 trained psychiatrists independently rated
these three cases; the numbers of depressive symptoms
listed in the DSM-IV-TR in the melancholic, reactive,
and one-in-between cases were fairly consistent among the
raters with 5.1 ± 0.3, 5.1 ± 0.3, and 4.9 ± 0.3 (mean ± SD),
respectively (detailed data available upon request). Simi-
larly, the NCS scores of the melancholic, reactive, and one-
in-between cases were also similar among the 11 raters
with −39.1 ± 2.0, 14.0 ± 2.6, -17.1 ± 3.3 (mean ± SD), re-
spectively. The inter-rater reliability of the NCS-II scores
were very high among the 11 raters with a Cronbach's
alpha of 0.999. In addition to case scenarios, we devel-
oped a 13-question survey regarding treatment options.
In this questionnaire, the details of this study were first
described. If the psychiatrists agreed to participate in
this study and provided written informed consent, they
were subsequently asked to read three case scenarios
and respond to questions regarding treatment for those
three cases on a 7-point Likert scale (1=”not appro-
priate”, 4=”cannot tell”, and 7=”appropriate”) (see
Additional file 3). The survey took approximately an
hour to complete. All questionnaires were sent and col-
lected by mail or by hand, under an anonymous state.
The following information was also collected: age,
sex, years in practice, work locations, and possession of
license of designated psychiatrist by the Ministry of
Welfare and Labor. All participants provided written in-
formed consent after complete description of the study
while the primary objective of this study was not
disclosed since it could have affected their response.
Statistical analysis
The data was analyzed using the SPSS 21.0 (IBM, New
York). Values of interest were compared among me-
lancholic, reactive, and one-in-between cases by the
Kruskal-Wallis test or Wilcoxon signed rank test when
appropriate. In addition, values of interest within cases were
also compared by the Kruskal-Wallis test or Wilcoxon
signed rank test when appropriate. A multiple regression
analysis was used to examine effects of psychiatrists' sex,
years in practice, work locations (i.e. psychiatric hospitals,
general hospitals, and community clinics), and possession
of license of designated psychiatrists on all the questions
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between). A value of p < 0.05 (two-tailed) was consid-
ered statistically significant. Bonferroni’s multiple com-
parison was applied when appropriate. This study was
approved by the Institutional Review Board of the Zama
Mental Clinic, and all subjects provided informed con-
sent after a complete description of the study. This
study complied with the Code of Ethics of the World
Medical Association, Declaration of Helsinki.
Results
Characteristics of participants
A total of 650 psychiatrists working in 108 different in-
stitutes (see Additional file 4) were asked to participate
in this survey; of these, 502 psychiatrists agreed and
completed the questionnaire (response rate: 77.2%). Two
hundred and sixty-eight respondents (53.3%) were affili-
ated with psychiatric hospitals, 168 (33.4%) with general
hospitals, 42 (8.4%) with community clinics, and 11
(2.2%) with other institutes such as government offices
while affiliations were not mentioned in 13 replies
(2.6%). Out of the respondents, the proportion of male
psychiatrists was higher compared to female doctors
(69.3% vs. 29.4%). The mean ± SD age and years in prac-
tice were 37.9 ± 12.8 years old and 14.5 ± 12.5 years, re-
spectively. The possession of a license of designated
psychiatrist by the Ministry of Welfare and Labor was







Antidepressant 5.9 ± 1.2 5.2 ± 1.4
Anxiolytic 4.2 ± 1.4 4.2 ± 1.24
Hypnotic 5.5 ± 1.1 5.4 ± 1.1
Antipsychotics 2.0 ± 1.2 2.0 ± 1.2
Electroconvulsive therapy 1.5 ± 0.9 1.3 ± 0.7
Psychotherapy 4.3 ± 1.4 4.7 ± 1.5
Environmental adjustment
Family intervention 4.6 ± 1.2 4.3 ± 1.6
Reduce his/her duties 5.6 ± 1.2 5.8 ± 1.1
Resting 5.7 ± 1.2 5.5 ± 1.3
Hospitalization 3.0 ± 1.3 2.7 ± 1.5
Diagnosis
Inform as “depression” 4.7 ± 1.7 4.1 ± 1.7
Inform as “depressive state” 5.7 ± 1.1 5.4 ± 1.3
Inform as “not a disease” 1.7 ± 1.0 2.0 ± 1.2
1 = “not appropriate”, 4 = “cannot tell”, and 7 = “appropriate”.Pharmacological treatment, electroconvulsive therapy,
and psychotherapy
Details of the results are shown in Table 1. The use of
antidepressants was positively endorsed by respondents
for the melancholic and one- in-between cases, while
they were more reluctant to use antidepressants for the
reactive case. When scores for “antidepressants” and
“anxiolytics” were compared within each case, psychia-
trists significantly preferred antidepressants over anxio-
lytics in the melancholic case (p < 0.001). In contrast, in
the reactive case, anxiolytics were more favored than
antidepressants. The mean scores of hypnotics, electro-
convulsive therapy (ECT), and antipsychotics in the mel-
ancholic case were significantly higher than those of the
reactive case, respectively. Although the magnitude of
the difference was minor, psychotherapy was given a
significantly higher score, compared to that for the mel-
ancholic and one- in-between cases. When attitudes
towards antidepressant and psychotherapy were com-
pared within each case, antidepressants were considered
more appropriate than psychotherapy in the melancholic
case. In contrast, in the reactive case, psychotherapy was
preferred over antidepressants.
Environmental adjustment
Categories of environmental adjustment (i.e. family inter-
vention, burden reduction, hospital admission, and resting)
were consistently judged appropriate for the melancholicree cases
Kruskal- Post-hoc, Mann–Whitney U,




3.6 ± 1.7 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
4.4 ± 1.5 0.010 Case1-Case3, Case2-Case3
5.0 ± 1.3 <0.001 Case1-Case3, Case2-Case3
1.7 ± 1.1 <0.001 Case1-Case3, Case2-Case3
1.2 ± 0.6 <0.001 Case1-Case3, Case2-Case3
4.9 ± 1.4 <0.001 Case1-Case2, Case1-Case3
3.5 ± 1.5 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
3.5 ± 1.5 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
3.6 ± 1.6 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
1.7 ± 1.0 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
2.2 ± 1.4 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
4.7 ± 1.6 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
3.7 ± 1.7 <0.001 Case1-Case2, Case1-Case3, Case2-Case3
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scores were especially large for restricting workload and
suggesting a leave from work (Table 1). Interestingly, the
score for reducing workload in the one-in-between case
was the highest among the three cases.
Diagnosis
For the three ways of informing diagnoses, telling pa-
tients that they were in a “depressive state” marked the
highest scores for melancholic, reactive, and one-in-
between cases, respectively (Table 1). Scores for inform-
ing patients that they suffered from “depression” were
significantly higher in the melancholic case compared to
the reactive case. In comparison, for informing patients
that their symptoms were “not a disease”, the mean
score in the melancholic case was significantly lower
than that in the reactive case.
Effects physicians’ characteristics on their responses
According to the multiple regression analysis, years in
practice and sex were found to have effects on some of
their responses as follows: years in practice (with in-
creasing years) on use of antidepressants for melancholic
(β: 0.034, 95% CI: 0.014 - 0.053, p = 0.001), one-in-
between (β: 0.033, 95% CI: 0.014 - 0.052, p = 0.001), and
reactive (β: 0.051, 95% CI: 0.034 - 0.068, p < 0.001) and
sex (female compared with male) on use of hypnotics for
one-in-between (β: 0.462, 95% CI: 0.231 - 0.694, p < 0.001)
and reactive (β: 0.428, 95% CI: 0.167 - 0.688, p = 0.001),
and psychotherapy for reactive (β: 0.491, 95% CI: 0.217 -
0.765, p < 0.001). Their sex (female compared with male)
showed effects on their responses on resting for one-in-
between (β: 0.446, 95% CI: 0.187 - 0.704, p = 0.001). More-
over, their years in practice also showed effects on their
responses in diagnoses: years in practice (with increasing
years) on “not a disease” for melancholic (β: -0.015, 95%
CI: -0.024 - -0.006, p = 0.001), “depressive disorder” for re-
active (β: 0.033, 95% CI: 0.018 - 0.049, p < 0.001), and “not
a disease” for reactive (β: -0.042, 95% CI: -0.058 - -0.026,
p < 0.001).
Discussion
This study sheds light on the overall attitude that Japanese
psychiatrists have towards treating MDD with different
clinical features. Historically, the term “melancholia” is
recognized as a distinctive clinical syndrome with a de-
fined underlying biology that is distinguishable from other
mood disorders. Efforts to define melancholic, however,
have declined in recent years following failures to validate
a distinction between melancholia and non-melancholia
[2]. In reality, MDD encompasses multiple subgroups that
differ meaningfully in phenomenology, natural history,
treatment response, and pathophysiology [2]. In this study,
we hypothesized that even though our three cases sharedcommon symptoms of MDD according to the DSM-IV,
selected treatment would vary according to melancholic
and reactive features in each case. Indeed, our results,
similarly, indicate that 85% of Japanese psychiatrists deem
antidepressants as appropriate for MDD patients with
melancholic features, compared to only 40% in MDD pa-
tients with reactive features. Melancholia, which has not-
withstanding the limitations discussed below, these results
show that Japanese psychiatrists may distinguish treatment
strategies when approaching MDD with melancholic and
reactive features.
Interestingly, our results are in contrast with recom-
mendations that are stated in current treatment guide-
lines for MDD. Most of the currently available treatment
guidelines recommend a choice of treatment options
based on the severity of the illness [14,15], and little
attention is drawn on the classical sub-categories of
depression within treatment guidelines (e.g., melancholic
and reactive depression). Under the present diagnostic
criteria, even though patients may be diagnosed as MDD
of matching severity, these same patients may present
with heterogeneous groups of symptoms. There have
been some reports that support the notion that melan-
cholic depression is often identified with severe depres-
sion, an assumption coming from the homogenous or
unitarian position [16]. However, the imaginary cases
presented in the present study were designed to be mild
in severity according to the DSM-IV. On the other hand,
the heterogeneous position suggests that some symp-
toms, such as psychomotor disturbances, indicate that
subtypes are biologically distinct and not a function of
severity [8]. In fact, depression can exist as a disease, a
disorder, a syndrome, and/or be normal, or abnormal re-
action to salient stressors. The findings that Japanese
psychiatrists take different treatment approaches to-
wards the three imaginary cases in this study unlikely fit
with a single dimensional or single categorical model.
Recent reports suggest that effectiveness of treatment
should be assessed according to the primary nosological
entity of the patients in question [17]. The results from
the present study suggest that Japanese psychiatrists ap-
proach MDD patients with melancholic and reactive fea-
tures as patients with different nosological entities, and
thus may choose different treatment strategies from their
clinical experience. This may not be unique to Japanese
psychiatrists, considering that the recent American Psychi-
atric Association (APA) guideline for treatment of MDD
recommends that factors such as psychosocial stressors
and problems in interpersonal relations be considered
when choosing treatments [18].
Although the dominant model for MDD today is unitar-
ian, which states that different presentations of depression
are all from the same spectrum and differ only in severity,
psychiatrists have traditionally utilized the binary approach
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this is still the case for a majority of psychiatrists, at least
in Japan. The debate of the idea of two depressions (e.g.,
melancholic and reactive) was very active almost four de-
cades ago, and the epidemiological studies in the 1960s
and 1970s found that the divisions of melancholic and
neurotic depressions did not imply differences in out-
comes. As a result, it had faded after the introduction of
the DSM-III [19] , which followed this debate. It did not,
however, completely disappeared, rather,it still seems to be
present with psychiatrists in Japan. A recent report that
comes from outside of Japan also supports this binary
approach; Fink et al. considered the proposition that
‘melancholia’, a time-tested diagnostic concept, should be
reinstated as a defined mood disorder in psychiatric classi-
fication [2]. Other mood disorders would best be labeled
‘Non-melancholic Mood Disorders’. Furthermore, they
even emphasized that the term ‘major depressive disorder’
should be discarded. The idea of choosing different treat-
ment strategies for different subgroups of depression may
not to be limited to Japan, and the pros and cons for this
type of treatment warrant further investigations. In the
present survey, anxiolytics were more favored than antide-
pressants for the reactive case. Typically, neurotic or react-
ive depression is associated with anxiety and mood
reactivity, and highly sensitive to psychosocial stressors
[7], It would also not be surprising if neurotic and major
depressive disorders also differed in treatment response.
In fact, Imlah conducted a four-week randomized con-
trolled trial to compare the effectiveness of alprazolam
to amitriptyline in patients with neurotic depression and
found that alprazolam was superior to amitriptyline [20].
Moreover, comparison of side effects showed a significant
difference in favor of alprazolam over amitriptyline [20].
However, easy use of benzodiazepines should be refrained
from in light of their potentially serious side effects such
as falls [21], cognitive impairment [22,23], and dependence
[24,25]. Furthermore, recent data on such direct compari-
son between benzodiazepines and antidepressants, espe-
cially selective serotonin reuptake inhibitors (SSRIs), are
not available in the literature. Still, these findings, com-
bined together with our results, may suggest the need of
revisiting potential merits and demerits of the use of ben-
zodiazepines for patients with reactive depression.
The result of our study must be interpreted in light of
a number of limitations. First, a possibility of selection
bias cannot entirely be rejected. The respondents were
distributed over a wide area of Japan, and the response
rate was as high as approximately 80%, yet the survey is
limited to psychiatrists who belong to a portion of insti-
tutes within our country. However, since our samples were
collected from multiple areas all over Japan, our results
are expected to be generally representative of Japanese
psychiatrists’ practice. Second, the cases in this study areimaginary cases, and not actual cases. In real clinical set-
tings, information on patients such as social history, family
history, and relevant stressors can be collected more thor-
oughly. Furthermore, demographic and clinical features
such as age, sex, duration of illness, and presentation of
our case scenarios may have affected the clinical treatment
choice; for example, this might have happened because
only the second case mentioned overwork, and in the
other two other cases, no mention was made of it. In
addition, the neurotic case may be little obvious; as a re-
sult, responders may have been led, to some extent, to
choose psychotherapy and prescribe some anxiolytics to
this young, forlorn man who has no history of previous
psychiatric illness. Moreover, a more thorough longitu-
dinal assessment of such a patient would have been ideal.
Third, we showed three cases in succession, so respon-
dents had time to compare the clinical features of the
three cases intentionally, which may have affected their re-
sponses. Fourth, it would have been ideal to ask reasons
for their responses in the present study although the re-
sponse rate may have been compromised. Finally, physi-
cian's treatment decisions are expected to be subject to
their educational and training background as well as direct
and indirect influence of current and local standard of
care, which indicates the need of further investigations in
order to provide a robust agreement on this issue.
Conclusions
The findings from this study indicate that Japanese psy-
chiatrists distinguish between MDD with melancholic
and reactive features, and thus choose different treat-
ment strategies regarding psychopharmacology and psy-
chotherapy. Thorough understanding of the differences
in psychiatrists’ practice between melancholic and re-
active depressions that we observed in this study is
critically important to appraise the current treatment
strategies for MDD. In light of a paucity of the data on
this clinically relevant issue, merits and demerits of these
different treatment strategies require further investiga-
tions in order to devise optimal treatment for MDD that
present with different clinical features.
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